SLN - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Silence Therapeutics PLC

Quarterly earnings per share dynamics on the GURU.Markets chart are independent of macro cycles, relying solely on the success of the therapy, where 48.30 serves as the base parameter value. Silence Therapeutics (SLN) suppresses pathogenic genes to treat cardiovascular pathologies. Business growth is based on long-term research alliances with pharma behemoths, excluding the acquisition of third-party assets.
Silence Therapeutics (SLN) - פילוחי מדדים ודוחות פיננסיים

Quarterly earnings per share (EPS) growth measures the dynamics of net income per share, reflecting the efficiency of business capitalization over the short term. For Silence Therapeutics (SLN), this metric depends on cost optimization through the implementation of AI models and the automation of oligonucleotide synthesis. By analyzing the quarterly EPS history, an investor can discern the speed at which the company adapts to market shocks. Sharp fluctuations in the trend line signal margin volatility, while a stable trend confirms the fundamental resilience of the assets.